April 25, 2026. 23 items curated for clinical relevance.
Above Threshold
Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
Alabama’s medical cannabis program aims to begin retail sales in spring 2026, requiring clinicians to understand licensing timelines and regulatory requirements for patient recommendations.
Read more →Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
Cannabis cannabinoids CBD and CBG show potential to reverse fatty liver disease in research, offering clinicians a possible therapeutic application for metabolic liver conditions in cannabis patients.
Read more →From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
The article examines the gap between commercial hemp product marketing and FDA regulatory enforcement, highlighting compliance challenges clinicians should understand when advising patients.
Read more →New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …
A new cannabis policy group integrates scientific evidence and patient insights to inform clinical guidelines, providing clinicians evidence-based frameworks for treatment decisions.
Read more →New Top Cannabis Regulator Sets Priorities In First Board Meeting
A newly appointed cannabis regulator outlined priorities in an inaugural board meeting, establishing foundational governance that affects clinical practice standards and patient access protocols.
Read more →Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead
Brazil’s evolving cannabis regulations present clinicians with updated prescribing frameworks and legal pathways that directly impact patient access, clinical practice standards, and therapeutic options in the region.
Read more →2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT
Two Cincinnati breweries challenged Ohio’s prohibition on THC-infused beverages, raising regulatory and legal questions relevant to cannabis product compliance and clinical cannabis availability.
Read more →New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG
Ohio legislation restricts THC-infused beverage distribution in retail settings, affecting patient access to alternative cannabis consumption methods and requiring clinicians to understand updated product availability for treatment recommendations.
Read more →Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo
Oregon lawmakers rejected a bill to limit THC potency in cannabis edibles, affecting product regulation and clinical considerations for patient dosing and safety protocols.
Read more →Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed
This article reviews formulation and fabrication methods for delivering cannabinoids through oral mucosal routes, which is clinically relevant for improving bioavailability and onset time compared to traditional ingestion.
Read more →Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
CBD-dominant cannabis products demonstrate measurable anxiety relief, providing clinicians with evidence-based therapeutic options for patient treatment protocols.
Read more →Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
A clinical trial demonstrates cannabis extracts’ efficacy in reducing myofascial pain, providing evidence-based data that clinicians can reference when evaluating cannabis as a treatment option for this condition.
Read more →As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely
I can’t complete this task because the article summary wasn’t provided—only the title is visible. To write an accurate sentence about what this covers and why it matters to cannabis clinicians, I would need the actual article text or summary.
Read more →Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch
Marijuana gummies sold in Ohio were recalled, requiring clinicians to monitor patients for potential adverse effects and verify product safety status with dispensaries.
Read more →New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire
A new organization has formed to prepare for upcoming Medicare pilot programs testing cannabidiol (CBD) in clinical settings, potentially expanding insurance coverage and clinical research opportunities.
Read more →Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA
This resource covers legal prohibition statuses and regulatory frameworks affecting marijuana, essential for clinicians to understand jurisdictional compliance and patient counseling requirements.
Read more →Louisiana lawmaker files bill to legalize recreational marijuana through licensed dispensaries
A Louisiana legislator introduced legislation enabling recreational marijuana sales via licensed dispensaries, potentially expanding patient access and creating regulated market opportunities for clinical practitioners.
Read more →Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
A Georgia mother’s homemade medical cannabis formulation has entered commercial dispensary distribution, demonstrating consumer-developed products entering regulated markets.
Read more →Virginia adult-use sales bills pass both chambers, head to conference committee! – Blog
Virginia’s adult-use cannabis sales bills advanced through both legislative chambers, requiring conference committee reconciliation before potential legalization of retail sales—relevant to clinicians for patient access and regulatory changes.
Read more →Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown
This article examines evidence supporting and opposing medical marijuana’s clinical use while noting uncertainty about Tennessee’s regulatory stance—relevant for clinicians evaluating therapeutic applications and legal practice implications.
Read more →2026 Utah legislature on cannabis, psychedelics and kratom – Fox 13
The 2026 Utah legislature is addressing regulatory and legal frameworks for cannabis, psychedelics, and kratom—critical issues affecting clinical practice, patient access, and legal prescribing authority in the state.
Read more →Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube
Georgia legislation would restrict police use of marijuana/cannabis/hemp odor alone as probable cause for searches, affecting law enforcement practices relevant to patient privacy and legal compliance.
Read more →Digest-Level Clinical Commentary
These items reflect a field in transition between regulatory fragmentation and clinical maturation, where emerging evidence for cannabinoids in specific conditions like anxiety and myofascial pain is being outpaced by a consumer market that operates largely outside evidence-based frameworks and quality controls. The proliferation of product-focused litigation and manufacturing recalls alongside genuine scientific advances suggests that cannabis medicine practitioners face an expanding gap between what controlled studies demonstrate and what patients can reliably access through legal channels. My practice must therefore emphasize rigorous patient selection, transparent discussion of evidence limitations, and careful attention to formulation consistency while advocating for regulatory standards that would better serve clinical rather than purely commercial interests.
The digest reflects an industry in transition between research validation and regulatory fragmentation, with emerging clinical evidence supporting cannabinoid efficacy for specific conditions like anxiety and myofascial pain while state-level regulatory frameworks remain inconsistent and sometimes contradictory. Product safety and standardization remain significant gaps, as evidenced by recalls and FDA enforcement actions occurring alongside expansion of medical programs and consumer availability. The medical cannabis field would benefit from harmonized regulatory standards that accommodate growing clinical data while ensuring consistent quality control and transparent product labeling across jurisdictions.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: